SCHEMBL7262005

SCHEMBL7262005

COc1cc2nc(-c3ccc(Cl)cc3)nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 8/20 0.72
EHMT2 Q96KQ7 11/20 0.69
KDM1A O60341 4/20 0.69
RCOR1 Q9UKL0 3/20 0.69
NSD3 Q9BZ95 2/20 0.67
EHMT1 Q9H9B1 2/20 0.67
DNMT3A Q9Y6K1 1/20 0.67
EZH2 Q15910 1/20 0.67
WHR1 P49842 1/20 0.65
LMNA P02545 1/20 0.64
MAPT P10636 1/20 0.64
NTSR1 P30989 1/20 0.64
HTT P42858 1/20 0.64
KMT2A Q03164 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
NPC1 O15118 1/20 0.63
MTOR P42345 1/20 0.63
RAB9A P51151 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15280229 0.87 NSD2 (0.80) NSD2EHMT2KDM1ARCOR1NSD3
SCHEMBL5530627 0.83 LMNA (0.70) NSD2EHMT2KDM1ARCOR1DNMT3A
SCHEMBL7261548 0.83 CCR4 (0.62) NSD2EHMT2EHMT1WHR1
SCHEMBL15280265 0.82 EHMT2 (0.77) NSD2EHMT2KDM1ARCOR1NSD3
SCHEMBL15280407 0.81 EHMT2 (0.94) NSD2EHMT2KDM1ANSD3EHMT1
SCHEMBL15280410 0.81 EHMT2 (0.98) NSD2EHMT2KDM1ANSD3EHMT1
SCHEMBL15280243 0.81 EHMT2 (0.75) NSD2EHMT2KDM1ARCOR1NSD3
SCHEMBL23073435 0.81 EHMT2 (0.86) NSD2EHMT2KDM1ANSD3EHMT1
SCHEMBL15280363 0.81 EHMT2 (1.00) NSD2EHMT2KDM1ANSD3EHMT1
SCHEMBL15280242 0.81 EHMT2 (0.86) NSD2EHMT2KDM1ANSD3EHMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613772-B1 Drugs such as 2-(p-chlorophenyl-4-(4-hydroxybutyl)amino-6,7,8 -trimethoxyquinazoline used for activation of guanylate cyclase and modulation of cyclic guanosine monophosphate AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-09-02 US disclosed
EP-1040101-A1 SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2000-10-04 EP disclosed
WO-1999032460-A1 SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-07-01 WO disclosed